A deep global recession. Risk-averse investors. Depressed valuations. Demanding regulators and payors. By any measure, these are challenging times. But are they unprecedented? What makes this crisis different? How are companies adapting, and what lies ahead? Ernst & Young — which has been tracking industry data since biotech's early days through 23 years of reports — brings unique historical context to the crisis. In this session, the firm will present key findings from Beyond Borders, Ernst & Young's Global Biotechnology Report 2009. Learn how the numbers held up — but also go beyond the data to identify emerging trends. How are fi rms moving beyond the borders of traditional solutions with business strategies, new funding sources and creative deals? How is the business of biotech going beyond business as usual?